Search bioRxiv⌕ Search

Biology subjects

Lo Martire, V.

Publications and source records attributed to Lo Martire, V..

2 recordsLinked to original sources

Paternally expressed imprinted Snord116 and Peg3 regulate hypothalamic orexin neurons

Imprinted genes are highly expressed in the hypothalamus; however, whether specific imprinted genes affect hypothalamic neuromodulators and their functions is unknown. It has been suggested that Prader-Willi syndrome (PWS), a neurodevelopmental disorder caused by lack of paternal expression at chromosome 15q11-q13, is characterised by hypothalamic insufficiency. Here, we investigate the role of the paternally expressed Snord116 gene within the context of sleep and metabolic abnormalities of PWS, and we report a novel role of this imprinted gene in the function and organisation of the two main neuromodulatory systems of the lateral hypothalamus (LH), namely, the orexin (OX) and melanin concentrating hormone (MCH) systems. We observe that the dynamics between neuronal discharge in the LH and the sleep-wake states of mice with paternal deletion of Snord116 (PWScrm+/p-) are compromised. This abnormal state-dependent neuronal activity is paralleled by a significant reduction in OX neurons in the LH of mutants. Therefore, we propose that an imbalance between OX- and MCH-expressing neurons in the LH of mutants reflects a series of deficits manifested in the PWS, such as dysregulation of rapid eye movement (REM) sleep, food intake and temperature control.\n\nHighlightsO_LISnord116 regulates neuronal activity in the lateral hypothalamus (LH), which is time-locked with cortical states of sleep.\nC_LIO_LILoss of Snord116 reduces orexin neurons in the LH and affects sleep homeostasis and thermoregulation in mice.\nC_LIO_LISnord116 and Peg3 independently control orexin expression in the LH.\nC_LIO_LIPaternally expressed alleles maximize the patrilineal effects in the control of REM sleep by the LH in mammals.\nC_LI

neuroscience↗

Long-term cardiovascular re-programming by short-term perinatal exposure to nicotine‘s main metabolite cotinine

BackgroundCotinine - a nicotine by-product and biomarker of passive perinatal tobacco smoke exposure - is historically considered to lack significant health effects. We challenged this notion and sought \"proof-of-concept\" evidence of the adverse developmental potential of exposure to this substance at real-life levels.\n\nMethodsPregnant C57 mice drank nicotine or cotinine-laced water for 6wks from conception (NPRE = 2% saccharin+100g nicotine/ml; CPRE = 2% saccharin + 10g cotinine/ml) or for 3wks after birth (CPOST = 2% saccharin + 30g cotinine/ml). Controls drank 2% saccharin (CTRL). At 17{+/-}1weeks male pups (CTRL n=6; CPOST n=6; CPRE n=8; NPRE n=9) were instrumented for EEG and blood pressure (BP) telemetry. We evaluated (i) cardiovascular control during sleep (at rest / during stress); (ii) arterial reactivity ex vivo; (iii) expression of genes involved in arterial constriction/dilation.\n\nResultsBlood cotinine levels (ELISA) recapitulated passive smoker mothers-infants. Pups exposed only to cotinine exhibited (i) mild bradycardia - hypotension at rest (p<0.001); (ii) attenuated (CPRE, p<0.0001) or reverse (CPOST; p<0.0001) BP reactivity to asphyxia; (iii) pronounced adrenergic hypo-contractility (p<0.0003), low Protein Kinase C (p<0.001) and elevated adrenergic receptor mRNA (p<0.05) (all drug-treated arteries). NPRE pups also exhibited endothelium-mediated dysfunction.\n\nConclusionsCotinine has subtle, enduring developmental consequences. Some cardiovascular effects of nicotine can plausibly arise via conversion to cotinine. Low-level exposure to this metabolite may pose unrecognized perinatal risks. Adults must avoid inadvertently exposing a fetus or infant to cotinine as well as nicotine.

physiology↗